Cereno Scientific - Logotype
  • Svenska
  • English
  • Home
  • Cereno Scientific
    • About us
    • Vision
    • Strategy
    • History
    • Management Team
    • Board Members
  • Cardiovascular diseases
    • Heart attacks
    • Stroke
    • Pulmonary embolism
    • Deep Vein Thrombosis (DVT)
    • Limitations of current therapy
  • Drug candidate CS1
    • CS1 increases the production of t-PA
    • CS1 reduces the production of PAI-1
    • New formulation
    • Product portfolio
  • Partners
  • Investor relations
    • The share
    • Articles of Association
    • Financial calendar
    • Financial reports
    • Investor relations contact
    • IR Contact
  • News
    • Press releases
    • Other news
    • Events
    • Media
    • Subscribe
  • Contact
  • Home
  • Cereno Scientific
    ▼
    • About us
    • Vision
    • Strategy
    • History
    • Management Team
    • Board Members
  • Cardiovascular diseases
    ▼
    • Heart attacks
    • Stroke
    • Pulmonary embolism
    • Deep Vein Thrombosis (DVT)
    • Limitations of current therapy
  • Drug candidate CS1
    ▼
    • CS1 increases the production of t-PA
    • CS1 reduces the production of PAI-1
    • New formulation
    • Product portfolio
  • Partners
  • Investor relations
    ▲
    • The share
    • Articles of Association
    • Financial calendar
    • Financial reports
    • Investor relations contact
    • IR Contact
  • News
    ▼
    • Press releases
    • Other news
    • Events
    • Media
    • Subscribe
  • Contact

Investor relations

  • Financial calendar
  • The share
  • Investor relations contact
  • Cereno on Spotlight Stock Market
  • Articles of Association
  • IR Contact
  • Financial reports

Articles of Association

To read Cereno Scientifics Article of Association, click here

Press & news

10 Dec

News

Cereno Scientific strengthens its pipeline for the second time this year Cereno Scientific is developing a platform of cardiovascular therapies in...

10 Dec

Press release

Cereno Scientific broadens its pipeline – signs agreement on acquisition of compound in preclinical phase Cereno Scientific announced today that the company has signed an...

20 Nov

News

Approved study and prestigious meetings in fibrosis put Cereno Scientific in the limelight Yesterday, news came that Cereno Scientific had received approval for...

Calendar

Nordic-American Life Science Conference 2019-12-04 - 2019-12-05

16th Global Cardiovascular Clinical Trialists Forum 2019-12-05 - 2019-12-07

LeadingBiotech: East/West CEO 2020-01-11 - 2020-01-12

Biotech Showcase™ 2020 2020-01-13 - 2020-01-15

More about us...

Subscribe for corporate news

Follow us on LinkedIn

Follow us on Twitter

Privacy policy

We are proud supporters of World Thrombosis Day. Read more

Contact Us: Cereno Scientific AB (publ) | Visiting address: Pepparedsleden 1, 431 83 Mölndal, Sweden | Postal address: Pepparedsleden 1, 431 83 Mölndal, Sweden | E-mail: info@cerenoscientific.com

© 2016-2019 Cereno Scientific AB (publ) | All rights reserved

We use cookies to ensure that we give you the best experience on our website.
If you continue to use this site we will assume that you are happy with it.
Ok